ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
사이클로스포린 의약품 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 성장률(CAGR) 6.4%로 22억 3,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 자가면역질환 유병률 증가, 장기 이식 사례 증가, 안구건조증 환자 수 증가, 사이클로스포린 치료에 대한 인식 증가, 의료 인프라 확대 등 여러 요인에 기인합니다. 예측 기간 동안 예상되는 주요 동향으로는 약물전달 시스템의 발전, 사이클로스포린 약물의 제형 개선, 무방부제 점안제 혁신, 사이클로스포린 약물의 제네릭 개발, 동물 의료에서의 사이클로스포린 채택 등이 있습니다.
장기 이식에 대한 수요 증가는 사이클로스포린 의약품 시장의 성장을 견인할 것으로 예상됩니다. 장기 이식이란 인체 내 손상되거나 기능 장애가 발생한 장기를 다른 사람의 건강한 장기로 대체하는 것을 말합니다. 장기 이식의 증가는 말기 장기 질환의 유병률 증가에 기인한 바가 크며, 의료 진단 및 치료법의 발전으로 환자의 수명이 연장되어 장기 이식이 필요할 정도로 오래 살 수 있는 사람이 늘어나고 있습니다. 사이클로스포린 약물은 이물질 조직을 거부하는 면역계의 자연적 반응을 억제하여 이식된 장기가 수혜자의 면역세포에 의해 공격받아 손상되는 것을 방지함으로써 장기 이식에 중요한 역할을 하고 있습니다. 예를 들어, 2024년 12월 호주 보건 복지 연구소는 2022년 호주에서 938건의 신장 이식이 이루어졌으며, 그 중 90%가 첫 신장 이식이었다고 보고했습니다. 이 중 76%는 사망한 기증자로부터, 24%는 살아있는 기증자로부터의 이식이었습니다. 이처럼 장기 이식에 대한 수요 증가가 사이클로스포린 의약품 시장의 성장을 촉진하고 있습니다.
사이클로스포린 의약품 시장의 주요 기업들은 표적 치료를 눈에 직접 전달할 수 있는 첨단 안과 솔루션 개발에 주력하고 있습니다. 안과용 의약품은 감염, 염증, 안구건조증과 같은 눈의 증상을 치료하기 위해 특별히 처방되며, 일반적으로 점안제, 연고, 젤 형태로 판매됩니다. 예를 들어, 2023년 6월 독일에 본사를 둔 바이오 제약회사 Novaliq GmbH는 미국 식품의약국(FDA)으로부터 최초의 무수, 무방부제 0.1% 사이클로스포린 점안제 VEVYE를 승인받았습니다. VEVYE는 안구건조증에 대한 혁신적인 치료제로, 단 4주 만에 큰 효과를 입증했습니다. 독자적인 무수 제형은 약물의 안정성을 높이고 환자의 편안함을 향상시키며 자극을 최소화합니다. 이번 승인은 안과용 약물전달에 있어 큰 진전이며, 안구 내 염증을 보다 정확하게 표적화할 수 있게 됐습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 사이클로스포린 의약품 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
최종 이용 산업 분석
세계의 사이클로스포린 의약품 시장 : 성장률 분석
세계의 사이클로스포린 의약품 시장 실적 : 규모와 성장, 2019-2024년
세계의 사이클로스포린 의약품 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 사이클로스포린 의약품 전체 시장(TAM)
제6장 시장 세분화
세계의 사이클로스포린 의약품 시장 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
경구
비경구
세계의 사이클로스포린 의약품 시장 : 약제 처방별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
캡슐
경구 용액
주사제
국소 제제
세계의 사이클로스포린 의약품 시장 : 용도별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
장기 이식
자가면역질환
안질환
피부질환
세계의 사이클로스포린 의약품 시장 : 최종사용자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원
전문 클리닉
재택 케어 설정
의약품 소매
세계의 사이클로스포린 의약품 시장 : 경구 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
캡슐
정제
경구 용액
세계의 사이클로스포린 의약품 시장 : 비경구 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
정맥주사
정맥내 주입
제7장 지역별·국가별 분석
세계의 사이클로스포린 의약품 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 사이클로스포린 의약품 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
사이클로스포린 의약품 시장 : 경쟁 구도
사이클로스포린 의약품 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Intas Pharmaceuticals Limited
Astellas Pharma Inc.
Apotex Inc.
Dr. Reddy's Laboratories Limited
Cipla Limited
Hikma Pharmaceuticals PLC
Santen Pharmaceutical Co. Ltd.
Biocon Limited
Glenmark Pharmaceuticals Limited
Alkem Laboratories Limited
Concord Biotech Limited
CKD Bio Corporation
ChemWerth Inc.
Strides Pharma Science Limited
Fishfa Biogenics
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
사이클로스포린 의약품 시장 2029년 : 새로운 기회를 제공하는 국가
사이클로스포린 의약품 시장 2029년 : 새로운 기회를 제공하는 부문
사이클로스포린 의약품 시장 2029년 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Cyclosporine drugs are a class of immunosuppressive medications primarily used to prevent organ rejection following transplants and to treat various autoimmune disorders. These medications work by inhibiting the activity of T-lymphocytes, a type of white blood cell involved in the immune response, thereby reducing inflammation and immune system overactivity.
Cyclosporine drugs come in two main types oral and parenteral. Oral cyclosporine medications are taken by mouth to suppress immune system activity. They are available in several formulations, including capsules, oral solutions, injectables, and topical treatments. These drugs are used for conditions such as organ transplantation, autoimmune disorders, ophthalmic conditions, and dermatological issues, and are prescribed in various settings, including hospitals, specialty clinics, homecare environments, and pharmaceutical retail outlets.
The cyclosporine drugs market research report is one of a series of new reports from The Business Research Company that provides cyclosporine drugs market statistics, including cyclosporine drugs industry global market size, regional shares, competitors with a cyclosporine drugs market share, detailed cyclosporine drugs market segments, market trends and opportunities, and any further data you may need to thrive in the cyclosporine drugs industry. This cyclosporine drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cyclosporine drugs market size has grown strongly in recent years. It will grow from $1.64 billion in 2024 to $1.75 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth observed during the historic period can be attributed to several factors, including the rising geriatric population, the increasing use of cyclosporine in ophthalmic treatments, a growing number of clinical trials for cyclosporine-based drugs, increased government support for drug research and development, and a surge in healthcare spending.
The cyclosporine drugs market size is expected to see strong growth in the next few years. It will grow to $2.23 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth projected during the forecast period can be attributed to several factors, including the increasing prevalence of autoimmune diseases, a rise in organ transplant cases, a growing number of patients with dry eye disease, heightened awareness of cyclosporine treatments, and expanding healthcare infrastructure. Key trends expected in the forecast period include advancements in drug delivery systems, improved formulations for cyclosporine drugs, innovation in non-preserved formulations for eye drops, the development of generic cyclosporine drugs, and the adoption of cyclosporine in veterinary medicine.
The growing demand for organ transplantation is expected to drive the expansion of the cyclosporine drugs market. Organ transplantation involves replacing a damaged or failing organ in a person's body with a healthy one from another individual. The rise in organ transplants is largely due to the increasing prevalence of end-stage organ diseases, with advancements in medical diagnostics and treatments extending patient lifespans, allowing more individuals to live long enough to require organ replacements. Cyclosporine drugs play a critical role in organ transplantation by suppressing the immune system's natural response to reject foreign tissues, helping to prevent the transplanted organ from being attacked and damaged by the recipient's immune cells. For example, in December 2024, the Australian Institute of Health and Welfare reported that 938 kidney transplants were performed in Australia in 2022, with 90% being first-time kidney transplants. Among these, 76% came from deceased donors, while 24% were from living donors. As such, the increasing demand for organ transplants is driving the growth of the cyclosporine drugs market.
Leading companies in the cyclosporine drugs market are focusing on developing advanced ophthalmic solutions to deliver targeted treatment directly to the eyes. Ophthalmic medications are specially formulated to treat eye conditions such as infections, inflammation, and dry eye, and are typically available in the form of drops, ointments, or gels. For example, in June 2023, Novaliq GmbH, a Germany-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for VEVYE, the first water-free and preservative-free 0.1% cyclosporine ophthalmic solution. Developed using Novaliq's proprietary EyeSol technology, VEVYE provides an innovative treatment for dry eye disease, demonstrating significant effectiveness within just four weeks. Its unique water-free formulation enhances drug stability, improves patient comfort, and minimizes irritation. This approval represents a major step forward in ophthalmic drug delivery, offering more precise targeting of inflammation in the eyes.
In October 2024, Novaliq GmbH, a Germany-based manufacturer of cyclosporine drugs, entered into a partnership with Laboratoires Thea to launch a ciclosporin eye drop solution in Europe as well as select Middle Eastern and North African (MENA) regions. This collaboration highlights a shared commitment to providing innovative treatments for patients suffering from dry eye disease. The upcoming introduction of Vevizye, a non-preserved cyclosporine eye drop solution, will expand the range of non-preserved treatments available for dry eye relief. Dry eye is a condition that significantly impacts the quality of life for many individuals, and this new treatment aims to offer a highly effective option. Laboratoires Thea is a France-based company that brings its expertise to the partnership, further strengthening the initiative.
Major players in the cyclosporine drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Limited, Astellas Pharma Inc., Apotex Inc., Dr. Reddy's Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Santen Pharmaceutical Co. Ltd., Biocon Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Limited, Concord Biotech Limited, CKD Bio Corporation, ChemWerth Inc., Strides Pharma Science Limited, and Fishfa Biogenics.
North America was the largest region in the cyclosporine drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cyclosporine drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the cyclosporine drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cyclosporine drugs market consists of sales of therapeutic drug monitoring kits, supportive care medications and cyclosporine active pharmaceutical ingredient. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cyclosporine Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cyclosporine drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cyclosporine drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cyclosporine drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Oral; Parenteral
2) By Drug Formulation: Capsules; Oral Solutions; Injectable Forms; Topical Preparations
3) By Application: Organ Transplantation; Autoimmune Disorders; Ophthalmic Disorders; Dermatological Disorders
4) By End-User: Hospitals; Specialty Clinics; Homecare Settings; Pharmaceutical Retail
Subsegments:
1) By Oral: Capsules; Tablets; Oral Solution
2) By Parenteral: Intravenous Injection; Intravenous Infusion
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Cyclosporine Drugs Market Characteristics
3. Cyclosporine Drugs Market Trends And Strategies
4. Cyclosporine Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Cyclosporine Drugs Growth Analysis And Strategic Analysis Framework
5.1. Global Cyclosporine Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Cyclosporine Drugs Market Growth Rate Analysis
5.4. Global Cyclosporine Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Cyclosporine Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Cyclosporine Drugs Total Addressable Market (TAM)
6. Cyclosporine Drugs Market Segmentation
6.1. Global Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
6.2. Global Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Capsules
Oral Solutions
Injectable Forms
Topical Preparations
6.3. Global Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Organ Transplantation
Autoimmune Disorders
Ophthalmic Disorders
Dermatological Disorders
6.4. Global Cyclosporine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Homecare Settings
Pharmaceutical Retail
6.5. Global Cyclosporine Drugs Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Capsules
Tablets
Oral Solution
6.6. Global Cyclosporine Drugs Market, Sub-Segmentation Of Parenteral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous Injection
Intravenous Infusion
7. Cyclosporine Drugs Market Regional And Country Analysis
7.1. Global Cyclosporine Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Cyclosporine Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
